The University of Oklahoma has embarked on a groundbreaking journey in the field of immunoengineering with the establishment of the Oklahoma Center for ImmunoEngineering (OCIE), propelled by an $11.5 million award from the National Institutes of Health (NIH). This ambitious initiative, funded through the NIH’s Centers of Biomedical Research Excellence program, aims to transform the way immune-related diseases are studied and treated. The five-year Phase I award marks a critical investment in the integration of engineering principles with immunology, creating a nexus for pioneering research that could reshape biomedical science and therapeutic modalities.
Immunoengineering represents a cutting-edge interdisciplinary domain that utilizes engineering tools to interrogate and modulate the immune system with unprecedented precision. This modulation involves either enhancing immune responses, as needed in cases of cancer or viral infections, or dampening them to treat autoimmune conditions. OCIE’s approach leverages this dual capability, seeking to systematically dissect immune mechanisms and develop innovative treatments tailored to diverse pathological contexts. The center is spearheaded by Wei Chen, Ph.D., an expert in cancer immunotherapy, and Chongle Pan, Ph.D., a leader in data science and computational biology, underscoring the center’s commitment to combining experimental and computational methodologies.
A critical infrastructure component of OCIE is the establishment of two synergistic research cores. The Immunomodulation Technology Core focuses on experimental laboratory work, providing researchers with advanced tools and methodologies to probe immune responses at the molecular and cellular levels. This core facilitates the development of novel immunotherapeutic strategies by enabling manipulation of immune cells and pathways in controlled laboratory settings. Complementing this, the Omics Data Science Core brings to bear state-of-the-art computational techniques and bioinformatics expertise. This core is dedicated to designing experiments, managing large-scale omics datasets, and applying machine learning algorithms to derive predictive models from complex immune system data.
The importance of integrating high-dimensional omics data with immunological experimentation arises from the sheer volume and complexity of information generated by modern biomedical research. Immunoengineering studies produce vast arrays of data spanning genomics, transcriptomics, proteomics, and metabolomics, which require sophisticated analytics to unravel the underlying biological insights. Through the synergy of experimental and computational cores, OCIE aims to build predictive frameworks that can forecast immune behavior under various therapeutic interventions, a critical step toward personalized medicine.
Dr. Wei Chen, leading the center, emphasizes the transformative potential of this integrated platform. Chen highlights his personal research in immunotherapy for late-stage cancer patients where the amalgamation of immunological insights with omics-driven data analysis has yielded innovative therapeutic avenues. OCIE aspires not only to be a hub of scientific innovation but also to serve as a collaborative platform for researchers across Oklahoma, fostering an ecosystem where discoveries rapidly translate into clinical applications that improve patient outcomes. This endeavor is positioned as a pioneering center nationally, with no existing comparable entity focusing on the convergence of immunomodulation and omics data science.
The Omics Data Science Core, under Chongle Pan’s guidance, is focused on harnessing artificial intelligence (AI), predictive modeling, and machine learning to provide actionable intelligence from immune system datasets. Because immune responses are highly dynamic and context-dependent, understanding them requires more than descriptive analysis—it requires predictive models that can simulate immune responses and predict therapeutic success. Pan’s work aims to democratize access to these computational tools, enabling researchers statewide to maximize the scientific yield of their immune-related studies.
OCIE also prioritizes the development of future scientific leaders by selecting and mentoring early-career investigators. Four junior faculty members have been appointed as research project leaders, each matched with experienced mentors from OU’s Norman and Health Sciences campuses. These young scientists spearhead innovative projects encompassing a broad range of immunoengineering challenges—from bat immunology related to coronavirus infection to sophisticated neuroimaging-guided immunotherapy in brain cancer, to computational and molecular investigations aimed at novel cancer vaccine design and understanding rare sarcoma immune microenvironments.
One project, led by Dr. Daniel Becker, explores the immune response of migratory bats to coronavirus infections, potentially offering vital clues to host-pathogen dynamics and natural viral resistance mechanisms. Dr. David Miller’s research focuses on glioblastoma, employing neuroimaging to guide immunotherapy approaches for one of the most aggressive and lethal brain tumors. Marmar Moussa’s work delves into T-cell receptor and antigen interactions, a fundamental aspect of developing effective peptide-based cancer vaccines. Meanwhile, Dr. Abdul Rafeh Naqash studies alveolar soft part sarcoma’s tumor immune microenvironment, identifying molecular vulnerabilities that could be therapeutically targeted.
Beyond project-specific research, OCIE fosters a vibrant scientific community through monthly seminars, interactive research roundtables, hands-on training workshops, and an annual symposium designed to catalyze interdisciplinary collaboration. A core mission of the center is to fund pilot research and promote team science, connecting basic immunologists, translational scientists, and clinicians to accelerate the journey from bench to bedside. This integrative approach aims to dismantle traditional silos and facilitate comprehensive understanding and manipulation of immune responses in multiple disease contexts.
The establishment of OCIE arrives at a strategic moment, given Oklahoma’s inclusion among the states benefiting from the NIH Institutional Development Award (IDeA) program. This program aims to enhance the research infrastructure in states that historically have received lower levels of NIH funding, thereby expanding national biomedical research capacity and equity. Through OCIE, Oklahoma becomes a vanguard for immunoengineering, reinforcing its scientific stature and capacity for biomedical innovation.
OCIE’s vision is nothing short of revolutionary. By converging immunology, engineering, and data science, the center establishes a model for precision immunomodulation. With capabilities spanning experimental manipulation and bioinformatic modeling, OCIE situates itself at the frontier of modern biomedicine, promising breakthroughs that could redefine immune system-based therapies. The center epitomizes the future of interdisciplinary biomedical research—where computation and experimentation coalesce to decode the immune system’s complexities and unlock new therapeutic vistas.
In summary, the University of Oklahoma’s Oklahoma Center for ImmunoEngineering leverages substantial NIH investment to create an unprecedented platform that integrates experimental immunomodulation technologies with advanced omics data science. Co-led by Drs. Wei Chen and Chongle Pan, OCIE is poised to make transformative advances in understanding and controlling immune function over diverse diseases such as cancer, viral infections, and autoimmune disorders. By supporting a new generation of interdisciplinary scientists and fostering collaboration, OCIE heralds a new era in immunoengineering, setting the stage for discoveries that hold the promise of vastly improved human health outcomes.
Subject of Research: Immunoengineering, Immunomodulation, Omics Data Science, Immunotherapy, Computational Biology
Article Title: University of Oklahoma Launches Pioneering Oklahoma Center for ImmunoEngineering with $11.5M NIH Award
News Publication Date: Not specified (most recent based on funding announcement)
Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/f8d658b4-8a4c-4e7e-b61d-c04c29ac2b93/Rendition/low-res/Content/Public
Image Credits: Jonathan Kyncl/University of Oklahoma
Keywords: Immunoengineering, Immunomodulation, Immune Regulation, Omics Data Science, Artificial Intelligence, Cancer Immunotherapy, Predictive Modelling, Machine Learning, Immune System, Biomedical Engineering, Systems Biology
